Literature DB >> 6160005

Failure to demonstrate any interaction between polyclonal rheumatoid factors and IgG antinuclear antibodies or other IgG autoantibodies.

L Scott-Morgan, R S Lloyd.   

Abstract

The autoantibody profile results from 750 randomly selected patients with rheumatoid factor (RF) and/or antinuclear antibody (ANA) positive tests were retrospectively analysed in order to discover if there was any evidence to show that the presence of polyclonal rheumatoid factors affects the incidence and titre of IgG-ANA in these patients. The incidence of IgG-ANA in the RF-positive group (34.4%) was significantly greater than that found in the RF-negative groups (19.6%) (P < 0.001), and there was no significant difference between the mean IgG-ANA titres of the two groups (P = 0.987). The possibility that the presence of IgM-RF in serum might be responsible for the inhibition of IgG-ANA was examined by treating the sera of selected patients who were RF-positive but IgG-ANA-negative with the dissociating agent D-penicillamine (DP). After treatment, IgG-ANA could not be detected in any of the sera. Similar studies were carried out to ascertain if there was a masking effect by RF on two other IgG autoantibodies, anti-keratin antibody (AKA) and gastric parietal cell antibody (GPCA). There was no evidence from these studies that the presence of RF affects the incidence of either AKA or GPCA. We conclude from these results that the presence of RF is not a significant factor controlling the incidence of either IgG-ANA or other IgG autoantibodies and that the routine treatment of RF-containing serum with a dissociating agent before testing for autoantibodies would be unnecessary.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6160005      PMCID: PMC1537016     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  10 in total

1.  THE ASSOCIATION OF RHEUMATOID FACTOR WITHANTINUCLEAR FACTOR ACTIVITY.

Authors:  J N MCCORMICK; J DAY
Journal:  Lancet       Date:  1963-09-14       Impact factor: 79.321

2.  Sheep cell agglutination test for rheumatoid arthritis; a clinico-pathological study.

Authors:  J BALL
Journal:  Ann Rheum Dis       Date:  1952-06       Impact factor: 19.103

3.  IgA and IgG reticulin antibodies in coeliac and non-coeliac patients.

Authors:  O E Eade; R S Lloyd; C Lang; R Wright
Journal:  Gut       Date:  1977-12       Impact factor: 23.059

4.  Antinuclear antibodies. Clinical significance of titers and fluorescence patterns.

Authors:  M Husain; J Neff; E Daily; J Townsend; F Lucas
Journal:  Am J Clin Pathol       Date:  1974-01       Impact factor: 2.493

5.  Immunofluorescent patterns and specificity of human antinuclear antibodies.

Authors:  Y B Bickel; E V Barnett; C M Pearson
Journal:  Clin Exp Immunol       Date:  1968-09       Impact factor: 4.330

6.  The range and specificity of antinuclear antibodies in systemic lupus erythematosus.

Authors:  D Alarcón-Segovia; E Fishbein; H Alcalá; E Olguín-Palacios; S Estrada-Parra
Journal:  Clin Exp Immunol       Date:  1970-04       Impact factor: 4.330

7.  Measles antibodies and autoantibodies in autoimmune disorders.

Authors:  D R Triger; T R Gamlen; E Paraskevas; R S Lloyd; R Wright
Journal:  Clin Exp Immunol       Date:  1976-06       Impact factor: 4.330

8.  Anti-keratin antibodies in rheumatoid arthritis.

Authors:  B J Young; R K Mallya; R D Leslie; C J Clark; T J Hamblin
Journal:  Br Med J       Date:  1979-07-14

9.  Interactions between IgM antiglobulins and IgG antinuclear antibodies. Some aspects of D-penicillamine activities.

Authors:  P S Mach; D Piatier; A Le Go; F Delbarre
Journal:  Clin Exp Immunol       Date:  1979-05       Impact factor: 4.330

10.  Immunofluorescent staining of rat gastric parietal cells by human antibody unrelated to pernicious anaemia.

Authors:  H K Muller; A R McGiven; R C Nairn
Journal:  J Clin Pathol       Date:  1971-02       Impact factor: 3.411

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.